Use of nomograms for predicting survival in patients with castrate prostate cancer.
Given the heterogeneity of prognoses in patients with castrate metastatic prostate cancer, the ability to accurately predict survival is vital for optimal patient counseling, selection of treatments, clinical trial design, and interpretation of clinical data. Over the past 20 years, several prognostic models have been developed in an attempt to refine the clinician's predictive ability. Early models were based on patients with more advanced disease. They included variables that are no longer regularly encountered today and involved cumbersome calculations that were not practical for everyday use in the clinic. Recently, 2 point-based nomograms have been developed based on pretreatment variables measured on a routine basis. These models provide a user-friendly format in which to make sophisticated predictions of survival. These models have improved our ability to predict the outcomes of patients with castrate metastatic disease. However, further work to identify novel prognostic markers to improve the accuracy of these predictions is needed.
Galsky
Matt
M
Department of Medicine, Joan and Sanford I. Weill Medical College of Cornell University, New York, New York, USA.
Kelly
William Kevin
WK
D000230:Adenocarcinoma / Q000097:blood / Q000401:mortality* / Q000628:therapy; D000465:Algorithms; D000469:Alkaline Phosphatase / Q000097:blood; D000726:Androgen Antagonists / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D019090:Case Management; D002986:Clinical Trials as Topic; D018450:Disease Progression; D005544:Forecasting; D006801:Humans; D017567:Karnofsky Performance Status; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D009363:Neoplasm Proteins / Q000097:blood*; D009919:Orchiectomy; D011379:Prognosis; D016016:Proportional Hazards Models; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000401:mortality* / Q000628:therapy; D012306:Risk
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D009363:Neoplasm Proteins; D007770:L-Lactate Dehydrogenase; D000469:Alkaline Phosphatase; D017430:Prostate-Specific Antigen